百洋医药：10月29日召开董事会会议

Group 1 - Baiyang Pharmaceutical (SZ 301015) announced on October 29 that its fourth board meeting will be held in a hybrid format, discussing the proposal for the sale of equity in an associated company [1] - For the year 2024, Baiyang Pharmaceutical's revenue composition is as follows: 92.5% from sales of pharmaceuticals and medical devices, 7.18% from brand services, and 0.32% from other businesses [1] - As of the report, Baiyang Pharmaceutical has a market capitalization of 13.8 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]